Lobbying Spend
$20K
Filings
4
Firms Hired
1
Active Period
2025–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
340B Transparency Act
2025 · fourth_quarter · Firm: NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS
S.2355, the Patients Deserve Price Tags Act; all provisions related to enhancing hospital and PBM transparency requirements to assist ERISA plan sponsors in fulfilling fiduciary duties; specifically provisions impacting employer-sponsored health plan reporting of cost and quality data to plan participants. H.R. 4317, the PBM Reform Act; provisions related to pharmacy benefit manager transparency and reporting requirements for ERISA group health plans; specifically sections regarding the 'ban on spread pricing' and the mandatory pass-through of rebates to employer plan sponsors. Lobbying related to reform of the 340B program like H.R. 3290, the 340B Transparency Act; provisions related to reporting requirements for covered entities; specifically issues concerning the impact of 340B contract pharmacy arrangements on employer-sponsored health plan costs and commercial market discounts. Lobbying related to the implementation and reform of the Independent Dispute Resolution (IDR) process established by the No Surprises Act; specifically advocating for improvements to the IDR Operations Rule to enhance administrative efficiency, reduce backlogs, and ensure fair payment determinations for ERISA plan sponsors.
Client expense: — · Firm income: —
Matched citations: H.R. 3290
PBM Reform Act of 2025
2025 · fourth_quarter · Firm: NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS
S.2355, the Patients Deserve Price Tags Act; all provisions related to enhancing hospital and PBM transparency requirements to assist ERISA plan sponsors in fulfilling fiduciary duties; specifically provisions impacting employer-sponsored health plan reporting of cost and quality data to plan participants. H.R. 4317, the PBM Reform Act; provisions related to pharmacy benefit manager transparency and reporting requirements for ERISA group health plans; specifically sections regarding the 'ban on spread pricing' and the mandatory pass-through of rebates to employer plan sponsors. Lobbying related to reform of the 340B program like H.R. 3290, the 340B Transparency Act; provisions related to reporting requirements for covered entities; specifically issues concerning the impact of 340B contract pharmacy arrangements on employer-sponsored health plan costs and commercial market discounts. Lobbying related to the implementation and reform of the Independent Dispute Resolution (IDR) process established by the No Surprises Act; specifically advocating for improvements to the IDR Operations Rule to enhance administrative efficiency, reduce backlogs, and ensure fair payment determinations for ERISA plan sponsors.
Client expense: — · Firm income: —
Matched citations: H.R. 4317
Patients Deserve Price Tags Act
2025 · fourth_quarter · Firm: NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS
S.2355, the Patients Deserve Price Tags Act; all provisions related to enhancing hospital and PBM transparency requirements to assist ERISA plan sponsors in fulfilling fiduciary duties; specifically provisions impacting employer-sponsored health plan reporting of cost and quality data to plan participants. H.R. 4317, the PBM Reform Act; provisions related to pharmacy benefit manager transparency and reporting requirements for ERISA group health plans; specifically sections regarding the 'ban on spread pricing' and the mandatory pass-through of rebates to employer plan sponsors. Lobbying related to reform of the 340B program like H.R. 3290, the 340B Transparency Act; provisions related to reporting requirements for covered entities; specifically issues concerning the impact of 340B contract pharmacy arrangements on employer-sponsored health plan costs and commercial market discounts. Lobbying related to the implementation and reform of the Independent Dispute Resolution (IDR) process established by the No Surprises Act; specifically advocating for improvements to the IDR Operations Rule to enhance administrative efficiency, reduce backlogs, and ensure fair payment determinations for ERISA plan sponsors.
Client expense: — · Firm income: —
Matched citations: S.2355
Source: Senate LDA